Aktie A3DK86 BIOAFFINITY TECHNOLOGIES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen bioAffinity Technologies, Inc.

Aktien

A3DK86

US09076W1099

BIAF

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 05.07.2024 		% 5 Tage % 1. Jan.
2,27 USD +4,61 % Intraday Chart für bioAffinity Technologies, Inc. +5,09 % +54,37 %
15.05. BioAffinity Technologies, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
01.04. BioAffinity Technologies, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
BioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath Lung Tests
BioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
BioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath Lung Sales and Increased Laboratory Volumes
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q1 Revenue $2.4M
BioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
BioAffinity Technologies News Update
BioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
BioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
BioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
BioAffinity Technologies, Inc. announced that it has received $2.624 million in funding
BioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
BioAffinity Technologies Closes $2.5 Million Equity Offerings
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
BioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
BioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
BioAffinity Technologies Reports Accelerating Sales Growth of CyPath Lung
BioAffinity Technologies, Inc. announced that it expects to receive $2.624 million in funding
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DK86 Aktie
  4. Nachrichten bioAffinity Technologies, Inc.
  5. Andere Sprachen